| Identification | Back Directory | [Name]
Selatinib | [CAS]
1275595-86-2 | [Synonyms]
Selatinib
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfinyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine | [Molecular Formula]
C29H26ClFN4O3S | [MDL Number]
MFCD28502047 | [MOL File]
1275595-86-2.mol | [Molecular Weight]
565.06 |
| Chemical Properties | Back Directory | [Boiling point ]
740.5±60.0 °C(Predicted) | [density ]
1.381±0.06 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO : 100 mg/mL (176.97 mM; Need ultrasonic) | [form ]
Solid | [pka]
8.39±0.19(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
Selatinib is a reversible and orally active dual EGFR and ErbB2 inhibitor with IC50s of 13 nM and 22.5 nM, respectively. Selatinib has anticancer effects[1]. | [IC 50]
EGFR: 13 nM (IC50); ErbB2: 22.5 nM (IC50) | [References]
[1] Meng-Na Wang, et al. First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects. Invest New Drugs. 2020 Dec;38(6):1826-1835. DOI:10.1007/s10637-020-00959-6 |
|
|